Israel - English - Ministry of Health

neopharm ltd, israel - fentanyl as citrate - tablets sublingual - fentanyl as citrate 100 mcg - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Israel - English - Ministry of Health

neopharm ltd, israel - fentanyl as citrate - tablets sublingual - fentanyl as citrate 200 mcg - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Israel - English - Ministry of Health

neopharm ltd, israel - fentanyl as citrate - tablets sublingual - fentanyl as citrate 300 mcg - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Israel - English - Ministry of Health

neopharm ltd, israel - fentanyl as citrate - tablets sublingual - fentanyl as citrate 400 mcg - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Israel - English - Ministry of Health

neopharm ltd, israel - fentanyl as citrate - tablets sublingual - fentanyl as citrate 600 mcg - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Israel - English - Ministry of Health

neopharm ltd, israel - fentanyl as citrate - tablets sublingual - fentanyl as citrate 800 mcg - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - solution for injection - trastuzumab 600 mg / 5 ml - trastuzumab - breast cancermetastatic breast cancerherceptin is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments. - in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive mbc, not previously treated with trastuzumab.early breast cancerherceptin is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). - following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) . - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. - in combination with neoadjuvant chemotherapy followed by adjuvant herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameterherceptin should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay .

Israel - English - Ministry of Health

medison pharma ltd - lisdexamfetamine dimesylate - capsules - lisdexamfetamine dimesylate 30 mg - lisdexamfetamine - vyvanse is a central nervous system (cns) stimulant indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients ages 6 years and above.vyvanse is indicated for the treatment of moderate to severe binge eating disorder (bed) for patient over 18 years.limitation of use:vyvanse is not indicated or recommended for weight loss. use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. the safety and effectiveness of vyvanse for the treatment of obesity have not been established

Israel - English - Ministry of Health

medison pharma ltd - lisdexamfetamine dimesylate - capsules - lisdexamfetamine dimesylate 50 mg - lisdexamfetamine - vyvanse is a central nervous system (cns) stimulant indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients ages 6 years and above.vyvanse is indicated for the treatment of moderate to severe binge eating disorder (bed) for patient over 18 years.limitation of use:vyvanse is not indicated or recommended for weight loss. use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. the safety and effectiveness of vyvanse for the treatment of obesity have not been established

Israel - English - Ministry of Health

medison pharma ltd - lisdexamfetamine dimesylate - capsules - lisdexamfetamine dimesylate 70 mg - lisdexamfetamine - vyvanse is a central nervous system (cns) stimulant indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients ages 6 years and above.vyvanse is indicated for the treatment of moderate to severe binge eating disorder (bed) for patient over 18 years.limitation of use:vyvanse is not indicated or recommended for weight loss. use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. the safety and effectiveness of vyvanse for the treatment of obesity have not been established